New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014

New research on innovative immunotherapies for melanoma, cervical cancer presented at ASCO 2014 -

New research on innovative immunotherapies for advanced melanoma high risk and cervical cancer were presented today at the 50th annual meeting of the American Society of Clinical Oncology (ASCO). These treatments - used alone or in combination - the fight against cancer by activating and amplifying the body's immune response to the disease
New studies find a strong activity with investigative drug for advanced melanoma, and show for the first time of ipilimumab. , A treatment already approved for advanced melanoma, can significantly reduce the risk of recurrent melanoma in some patients with earlier stage disease. In addition, another small trial reported only once, treatment of personalized immunotherapy induces complete remissions and sustainable in a small number of women with advanced cervical cancer -. A disease with few or no effective treatment options
"the field of immunotherapy has exploded over the past decade, and more and more patients benefit," Steven said press O moderator 'Day, MD, ASCO expert and associate professor of clinical medicine at the University of Southern California, Keck School of medicine. "to have a potential new way to keep the remote melanoma is a major advance for patients live in constant fear of recurrence after surgery. It is incredibly exciting that we decided to extend the benefits of immunotherapy beyond melanoma, diseases like cervical cancer where. patients need urgently better options "
of Featured studies include:
ipilimumab adjuvant improves recurrence-free survival in patients with stage high risk III melanoma: study marks the first time aid ( post-surgery) ipilimumab was effective in the early stage melanoma, although the side effects are significant
PD-1 immunotherapy targeting MK-3475 has high activity and long duration against metastatic melanoma. Grand phase I trial found high survival rates in patients with advanced melanoma, including those previously treated with ipilimumab; survival rate at one year was 69 percent in all subgroups of patients
Combination immunotherapy with ipilimumab and nivolumab realizes long-term survival for patients with advanced melanoma :. Monitoring data updated from an expanded Phase I study show concomitant treatment with ipilimumab and anti-PD-1 nivolumab yields strong, sustainable responses and survival rates
HPV targeted adoptive T cell therapy may provide a new strategy for personalized cancer advanced cervical :. Early study HPV immunotherapy -targeted shows promising activity in metastatic cancer of the cervix, a drive to treat the disease with few effective treatment options.